Healthy ParticipantsPhase 1NCT07765160
Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants
A Phase 1 study testing SAD: subcutaneous injection in the abdomen and MAD: subcutaneous injection in the abdomen in people with Healthy Participants and Overweight or Obese Participants, run by Innovent Biologics (Suzhou) Co. Ltd. at 1 site in China.
Trial summary
Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Participants, Overweight or Obese Participants
- What is being tested?
- SAD: subcutaneous injection in the abdomen and MAD: subcutaneous injection in the abdomen
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 96 participants
- Where
- 1 siteChina
- Study dates
- 30 Aug 2026to 10 Dec 2027
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- All participants in Part A (SAD) and Part B (MAD) must meet inclusion criteria 1-3:
- 1.The age at the time of informed consent should be between 18 and 65 years old (including both values), and there is no gender restriction.
- 2.Female participants who are fertile and male participants whose partners are fertile must agree to use the contraceptive methods specified in the protocol during the study period and within 90 days after the last administration. The pregnancy test results of female participants with fertility before randomization must be negative. Female participants should not breastfeed. Male/female participants must be willing to avoid donating sperm/eggs during the study period and within 90 days after the last administration.
- 3. Be able to understand the procedures and methods of this research, be willing to strictly follow the clinical trial protocol to complete this trial, and voluntarily sign the informed consent form.
- Participants of Part A (SAD) also need to meet inclusion criteria 4-6:
- 4. Participants who were determined by the researchers to be normal or abnormal based on the results of various examinations such as medical history, vital signs, physical examination, 12-lead electrocardiogram, laboratory tests, infectious disease screening, chest X-ray, and abdominal color Doppler ultrasound, but were determined by the researchers to have no clinical significance.
Show all 11Show fewer
- 5. During screening, 20 kg/m ² ≤BMI <28 kg/m ²;
- 6. When screening, the standard weight should be ≥50 kg
- Participants of Part B (MAD) also need to meet inclusion criteria 7-8:
- 7. During screening, 24 kg/m2 ≤BMI ≤40 kg/m2;
- 8. The standard weight change within 3 months prior to screening should be no more than 5kg (reported by the participants themselves).
Who cannot join
- All participants in Part A (SAD) and Part B (MAD) who meet any one of the exclusion criteria 1-17 cannot be included in the corresponding stage of the study:
- 1.Participants may be allergic to any component of the investigational drug, GLP-1 or Amylin receptor agonists (see Appendix 3 for details), or have used GLP-1 or Amylin receptor agonists within 3 months prior to screening;
- 2. A history of diabetes, or a glycated hemoglobin level of ≥6.5% during the screening period, or a fasting blood glucose level of ≥7.0 mmol/L;
- 3. Previous history of thyroid C-cell carcinoma, multiple endocrine adenomatosis (MEN) 2A or 2B, or related family history, or calcitonin ≥20 ng/L at screening;
- 4. A history of acute or chronic pancreatitis in the past, or amylase or lipase >1.5× upper limit of the normal range (ULN) at the time of screening;
- 5. Alanine aminotransferase >1.5×ULN during the screening period; Or aspartate aminotransferase >1.5×ULN; Or total bilirubin >1.5×ULN;
Show all 28Show fewer
- 6. During the screening period, the hepatitis B surface antigen is positive, or the hepatitis C antibody is positive, or the syphilis helix specific antibody is positive, or the HIV antibody is positive;
- 7. Abnormal 12-lead electrocardiogram (ECG) during the screening period and judged by the researcher as having clinical significance, or ECG QTcF >450 ms, or heart rate <60 beats per minute or >100 beats per minute;
- 8. Having a history of suicidal behavior, or being considered to have a significant suicide risk at present, or having a PHQ (Depression Screening Scale) score of ≥15 at the time of screening, or being classified as category 4 or 5 on the C-SSRS (Columbia Suicide Severity Scale) at the time of screening, or choosing "yes" in suicidal behavior or suicidal ideation;
- 9. Use of prescription and over-the-counter drugs within 2 weeks before screening or within 5 half-lives (excluding topical eye/nasal drops and creams without systemic exposure risk);
- 10. Have participated in any clinical trials of drugs (or within five half-lives) or medical devices within three months prior to screening, or plan to participate in clinical trials of other drugs or medical devices during the trial period;
- 11. Those who consumed an average of more than 2 units of alcohol per day in the three months prior to screening (1 unit of alcohol ≈360 mL of beer with an alcohol content of 5% or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine with an alcohol content of 12%), or those who were unable to quit drinking during the trial period, or those with a positive breath test for alcohol;
- 12. Smoking more than 5 cigarettes per day within the 3 months prior to screening;
- 13. Those who have a history of drug abuse within the five years prior to screening, or have used drugs within the three months prior to screening, or have a positive urine drug screening result;
- 14. Blood donation and/or blood loss within 3 months prior to screening ≥450 mL, or having undergone bone marrow donation, blood transfusion or severe blood loss, or having hemoglobinopathy, hemolytic anemia, sickle cell anemia, or hemoglobin <120 g/L (for men) or <110 g/L (for women);
- 15. Inability to tolerate venipuncture for blood collection or fainting at the sight of needles and blood;
- 16. Those whose injection site assessment is considered abnormal by the researchers;
- 17. The researcher believes that there are other factors that are not suitable for participating in this trial.
- Participants in Part A (SAD) cannot be included in the study if they meet the following exclusion criteria:
- 18. During the screening period, the systolic blood pressure is less than 90mmHg or ≥140mmHg, or the diastolic blood pressure is less than 50 mmHg or ≥90mmHg, or the pulse rate is less than 60 beats per minute or >100 beats per minute.
- Participants in Part B (MAD) who meet any one of the exclusion criteria 19-25 cannot be included in the study:
- 19. The following diseases (including but not limited to gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases) with clinical findings indicating clinical significance within 12 months prior to screening;
- 20. A history of life-threatening diseases (excluding basal cell skin cancer or squamous cell skin cancer) within the five years prior to screening;
- 21. Previous researchers have considered clinically significant gastric emptying abnormalities (for example, severe gastroparesis or gastric outlet obstruction), who have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery, or have been taking drugs that directly affect gastrointestinal motility for a long time;
- 22. During the screening period, systolic blood pressure is less than 90 mmHg or ≥160mmHg, or diastolic blood pressure is less than 50 mmHg or ≥100mmHg, or pulse rate is less than 60 beats per minute or >100 beats per minute.
- 23. For drugs that have been used or are currently being used within the three months prior to screening and may cause significant standard weight gain, including but not limited to: tricyclic antidepressants, psychotropic drugs or sedatives (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenylhydrazine, chlorpromazine, thiridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts);
- 24. Having used weight-loss drugs or alternative therapies within the three months prior to screening, including but not limited to: GLP-1 or Amylin receptor agonists, orlistat, sibutramine hydrochloride, phenylpropanolamine, chlorphenimidole, butylamine, clocaserin hydrochloride, fentamine, fentamine/topiramate mixture, anferylene and naltrexone/bupropion mixture.
- 25. Thyroid tumors or thyroid nodules with a Thyroid Imaging Reporting and Data System (TI-RADS) grade of ≥4 were present during screening.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 201107
Jing Zhang, 021-52887926, Zhangj_fudan@163.com
Guoying Cao, 021-52888195, 13816357099@163.com
About this study
Official title: A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of a Single Subcutaneous Administration of IBI3040 in Healthy Participants and Multiple Subcutaneous Administrations in Overweight or Obese Participants
Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.
- Being tested
- SAD: subcutaneous injection in the abdomen, MAD: subcutaneous injection in the abdomen
- Medical subject headings
- Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SAD: subcutaneous injection in the abdomenDrug
SAD: Single subcutaneous administration, with a safe follow-up period of 60 days
MAD: subcutaneous injection in the abdomenDrug
MAD: Multiple administration, subcutaneous injection
| Study group | Role | What they receive |
|---|---|---|
| IBI3040 | Experimental | IBI3040, specification 0.6 ml:2.4 mg, injection, subcutaneous injection in the abdomen Receives: Drug: SAD: subcutaneous injection in the abdomen; Drug: MAD: subcutaneous injection in the abdomen |
| IBI362 | Active comparator | IBI362, specifications: 0.5 ml:2 mg, 0.5 ml:4 mg and 0.5 ml:6 mg, injection, subcutaneous injection in the abdomen Receives: Drug: MAD: subcutaneous injection in the abdomen |
| IBI3040 Placebo | Placebo comparator | IBI3040 Placebo (without active ingredients), specification 0.6ml, injection, subcutaneous injection in the abdomen Receives: Drug: SAD: subcutaneous injection in the abdomen; Drug: MAD: subcutaneous injection in the abdomen |
What is being measured
The primary outcome is the main question the study is designed to answer.
SAD: The incidence rate of adverse events (AE)
Measured: through study completion, an average of 60 days
SAD: The incidence rate of serious adverse events (SAE)
Measured: through study completion, an average of 60 days
SAD: Number of subjects with clinically significant changes in physical examination results
Measured: through study completion, an average of 60 days
SAD: Number of subjects with clinically significant changes in vital signs
Vital signs including body temperature, pulse, respiratory rate and blood pressure
Measured: through study completion, an average of 60 days
SAD: Number of participants with abnormal laboratory tests results
laboratory tests including Blood routine、Blood Biochemistry (including blood lipids)、Coagulation routine、Urine routine、blood amylase、blood lipase、Pregnancy test、Calcitonin and Glycated hemoglobin (HbA1c)
Measured: through study completion, an average of 60 days
SAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram
Measured: through study completion, an average of 60 days
MAD: The incidence rate of adverse events (AE)
Measured: through study completion, an average of 20 weeks
MAD: The incidence rate of serious adverse events (SAE)
Measured: through study completion, an average of 20 weeks
MAD: Number of subjects with clinically significant changes in physical examination results
Measured: through study completion, an average of 20 weeks
MAD: Number of subjects with clinically significant changes in vital signs
Vital signs including body temperature, pulse, respiratory rate and blood pressure
Measured: through study completion, an average of 20 weeks
MAD: Number of participants with abnormal laboratory tests results
laboratory tests including Blood routine、Blood Biochemistry (including blood lipids)、Coagulation routine、Urine routine、blood amylase、blood lipase、Pregnancy test、Calcitonin and Glycated hemoglobin (HbA1c)
Measured: through study completion, an average of 20 weeks
MAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram
Measured: through study completion, an average of 20 weeks
Secondary outcomes (17)
SAD: area under the curve (AUC)
Measured: through study completion, an average of 60 days
SAD: maximum concentration (Cmax)
Measured: through study completion, an average of 60 days
SAD: time to maximum concentration (Tmax)
Measured: through study completion, an average of 60 days
SAD: clearance (CL/F)
Measured: through study completion, an average of 60 days
SAD: apparent volume of distribution (V/F)
Measured: through study completion, an average of 60 days
SAD: half-life (T1/2)
Measured: through study completion, an average of 60 days
SAD: Anti-drug antibodies (ADA)
Measured: through study completion, an average of 60 days
SAD: neutralizing antibodies (NAb)
Measured: through study completion, an average of 60 days
MAD: area under the curve (AUC)
Measured: through study completion, an average of 20 weeks
MAD: maximum concentration (Cmax)
Measured: through study completion, an average of 20 weeks
MAD: time to maximum concentration (Tmax)
Measured: through study completion, an average of 20 weeks
MAD: clearance (CL/F)
Measured: through study completion, an average of 20 weeks
MAD: apparent volume of distribution (V/F)
Measured: through study completion, an average of 20 weeks
MAD: half-life (T1/2)
Measured: through study completion, an average of 20 weeks
MAD: Anti-drug antibodies (ADA)
Measured: through study completion, an average of 20 weeks
MAD: neutralizing antibodies (NAb)
Measured: through study completion, an average of 20 weeks
MAD: The change in body weight from baseline and the rate of change
Measured: through study completion, an average of 20 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study start30 Aug 2026 (estimated)
- Primary completion10 Nov 2027 (estimated)
- Study completion10 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy ParticipantsStudies of the same condition, open and under way.
- More trials run by Innovent Biologics (Suzhou) Co. Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07765160
- Sponsor's protocol ID
- CIBI3040A101
- Status last verified
- Aug 2026
- First submitted
- 11 Aug 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No